NoBACZ Healthcare raises £4.8m to bring its liquid bandage technology to the global market
Cambridge, 30th September, 2025: NoBACZ Healthcare, a University of Cambridge spinout developing novel products that change the way lesions and wounds are treated in livestock and horses, has raised a £4.8m funding round led by The Yield Lab, with participation from Adjuvo, ACF Investors, the University of Cambridge, Parkwalk, The FSE Group, and Cambridge Enterprise Ventures. The investment will accelerate the global commercialisation of NoBACZ’s patented ‘liquid bandage’ technology, and support the launch of new products.
Wounds on livestock and horses are typically treated with antibiotics and then covered with cloth bandages. However, this approach is often ineffective in agricultural environments where slurry can contaminate wounds, washing off antibiotics and turning bandages into infection risks.
NoBACZ Healthcare was founded by Dr Jonathan Powell and Dr Nuno Faria following their research at the University of Cambridge’s Department of Veterinary Medicine into how the body naturally builds and utilises mineral structures for its own benefit. Initially developed to solve the problem of digital dermatitis, a disease that is painful for animals and costly for farmers – and affects a quarter of all cows at any given time – their research led to the creation of NoBACZ’s patent-protected ‘liquid bandage’.
The result is a robust, flexible, and waterproof coating that can be applied as a gel, dip or spray. Unlike antibiotics and cloth bandages, it creates an instant protective barrier that seals out slurry and bacteria, allowing lesions to heal without the risk of infection even in harsh environments. The coating is durable, yet biodegradable, safe in the food chain, intuitive to apply, and antibiotic-free. Independent large-scale studies have validated its effectiveness, including a Flock Health trial on 6,840 lambs, which demonstrated significantly lower mortality rates and higher market weights compared to the current industry standard.
NoBACZ is already active in international markets, with an initial focus on the UK, Ireland and Europe, alongside launches in New Zealand, the USA and Australia. The investment will be used to finalise its new pipeline of products and accelerate the commercialisation and global distribution of its existing products. In parallel with the veterinary product roadmap, they are also defining their human product opportunity.
Dr Jonathan Powell, CEO and Co-founder of NoBACZ Healthcare, said: “We founded NoBACZ Healthcare with the goal of transforming healthcare solutions for a more sustainable future whilst reducing antibiotic use. This new funding will fuel our expansion as we broaden our global product reach, launch our new range of products for the equine industry and continue to develop innovative veterinary healthcare solutions. In parallel to the veterinary product roadmap, we are starting to define our human product opportunity. We are at a pivotal and exciting moment in our company’s journey, and we look forward to working with our new and existing investors on the next phase of our growth.”
Gentiane Gorlier – General Partner at The Yield Lab, said: “At The Yield Lab, we are delighted to deepen our support for NoBACZ, having also backed the company in its previous round. The team has consistently impressed us with their vision, execution, and commitment to transforming animal healthcare with sustainable, antibiotic-free solutions. Leading this round reflects our confidence in NoBACZ’s leadership and technology, and we believe the company is poised for significant global impact.”
Mark Foster-Brown, CEO of Adjuvo, said: “For too long, topical antibiotics and bandages have offered inadequate solutions for animal wound care. NoBACZ’s patented platform technology sets a new benchmark, delivering ground-breaking results while aligning with Adjuvo’s mission to back innovation in underserved sectors. Led by globally recognised experts from the University of Cambridge, we are proud to support the team as they transform wound management in livestock and beyond.”
Tim Mills, Managing Partner at ACF Investors, said: “NoBACZ is a fantastic example of an innovative business emerging from the Cambridge University ecosystem. With significant market traction already established, scaling internationally and bringing new products to the market, the team are changing the game when it comes to livestock and equine wound care. We are excited to be backing Jonathan and his team as they reach the next stage of development.”
Dr Christine Martin, Head of Ventures at Cambridge Enterprise, said: “This is our third investment in NoBACZ, a company we are thrilled to continue supporting as they expand their innovative wound dressing solution to help a growing number and range of animals.”
– ENDS –
About NoBACZ
NoBACZ Healthcare is a wound protection company specialising in sustainable, rapid-setting flexible barrier dressings. Its products are developed using a natural polymer in a patented formulation that sets on contact with wounds to provide a waterproof barrier, keeping environmental pathogens and contaminants out and facilitating natural skin repair in a favourable environment.
For further information, please visit nobacz.com/
About The Yield Lab Europe
Yield Lab Europe invests in young European AgriFoodTech businesses, with the aim of enhancing the sustainability and efficiency of worldwide production systems for food and agriculture, as well as improving their profitability. This encompasses technologies in the fields of crop production, animal welfare, precision agriculture, horticulture, food ingredients,
supply chains and logistics, and food packaging and processing. So far, the fund has realised 32 investments.
To find out more, please visit https://theyieldlab.com/
About Adjuvo
Adjuvo is a London-based investment syndicate founded in London in 2015. Adjuvo has over 200 experienced business leaders as members who collectively invest in early-stage high-growth British pioneers. True to the vision of Adjuvo meaning “I help”, the network is committed to adding value beyond capital. This includes making strategic introductions, sharing expertise with founders and leadership teams, and championing UK entrepreneurship, innovation and job creation.
To find out more, please visit adjuvo.com/
About ACF Investors
Launched in 2011, ACF Investors (formerly the Angel CoFund) is a privately managed and commercially focused venture capital fund that works alongside sector smart business angels to invest in high-potential SMEs across the UK, directly providing funding to support exceptional businesses.
To date, ACF Investors has supported more than 120 companies, including such names as Ebury, Gousto, Creo Medical, and Form3, providing more than £85 million in direct investment alongside more than £500 million from business angels and other investors, making it one of the most active early-stage investors in the country.
To find out more, please visit www.acfinvestors.com/
About Parkwalk
Parkwalk is the UK’s most active investor in university spinouts, backing transformative technologies developed by the country’s leading universities and research organisations. As the leading growth EIS fund manager, with £500 million in assets under management, Parkwalk has invested in over 200 companies through its Parkwalk Opportunities and Knowledge Intensive EIS Funds, as well as through enterprise and innovation funds managed for the Universities of Cambridge, Oxford, Bristol, and Imperial College. In 2025, Parkwalk introduced the Northern Universities Venture Fund, targeting opportunities emerging from the Universities of Leeds, Liverpool, Manchester, and Sheffield.
Parkwalk focuses on investing in companies addressing real-world challenges with IP-protected innovations across a broad range of sectors, including life sciences, artificial intelligence, quantum computing, advanced materials, genomics, cleantech, future mobility, medtech, and big data.
In partnership with our parent company, IP Group, we are dedicated to unlocking the potential of UK university research, supporting businesses throughout their journey from spinout to scale-up and from laboratory to market.
For more information please go to: https://parkwalkadvisors.com/
About The FSE Group
The FSE Group has been providing high-growth SMEs with accessible market-gap funding since 2002. We work with stakeholders and partners, including Cambridgeshire and Peterborough Combined Authority, British Business Bank, Funding Yorkshire, Funding London and Local Enterprise Partnerships, to deliver regional funding that supports job creation and economic prosperity. With a range of funds that combine commercial return with an economic impact rationale, FSE is committed to investing in sustainable businesses that will grow, provide employment, and generate economic benefit in an environmentally and socially responsible manner.To find out more, please visit https://www.thefsegroup.com/
About Cambridge Enterprise Ventures
Part of Cambridge Enterprise, Cambridge Enterprise Ventures is the investment arm of the University of Cambridge. We support a diverse range of entrepreneurs and founders by investing University of Cambridge capital into high potential, high impact early-stage businesses. As venture investors, we help founders by building high value-add syndicated rounds, providing board experience and leveraging long standing connections to the Cambridge ecosystem and beyond.
To find out more, please visit www.enterprise.cam.ac.uk/ventures
Coverage appeared: